Utility of ATP7B in prediction of response to platinum-based chemotherapy in urothelial bladder cancer

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 3731-3738

  Schmid, Sebastian Christoph ^a   Schuster, Tibor ^b   Horn, Thomas ^a   Gschwend, Jürgen ^a   Treiber, Uwe ^a   Weirich, Gregor ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

ATP7B; Bladder cancer; Chemotherapy; Cisplatin; LOH; Urothelial carcinoma

Indexed keywords

CISPLATIN; DNA; WILSON DISEASE PROTEIN;

ADULT; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHROMOSOME 13Q; CLINICAL ARTICLE; DNA EXTRACTION; DNA SEQUENCE; FEMALE; GENE MUTATION; GENETIC SCREENING; HETEROZYGOSITY LOSS; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ATP7B; BLADDER CANCER; CHEMOTHERAPY; CISPLATIN; LOH; UROTHELIAL CARCINOMA;

ADENOSINE TRIPHOSPHATASES; ADULT; AGED; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CATION TRANSPORT PROTEINS; CHROMOSOMES, HUMAN, PAIR 13; CISPLATIN; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 84884999042     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Collaborators GBoDS: Global Burden of Disease Study 2010 (GBD 2010): Results by Cause 1990-2010. Institute for Health Metrics and Evaluation, University of Washington, 2010.
2. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM and Conte PF: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18: 3068-3077, 2000.
3. Sinani D, Adle DJ, Kim H and Lee J: Distinct mechanisms for Ctr1-mediated copper and cisplatin transport. J Biol Chem 282: 26775-26785, 2007.
4. Hall MD, Okabe M, Shen DW, Liang XJ and Gottesman MM: The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48: 495-535, 2008.
5. Petrukhin K, Lutsenko S, Chernov I, Ross BM, Kaplan JH and Gilliam TC: Characterization of the Wilson disease gene encoding a P-type copper transporting ATPase: genomic organization, alternative splicing, and structure/function predictions. Hum Mol Genet 3: 1647-1656, 1994.
6. Lutsenko S, Barnes NL, Bartee MY and Dmitriev OY: Function and regulation of human copper-transporting ATPases. Physiol Rev 87: 1011-1046, 2007.
7. Safaei R and Howell SB: Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 53: 13-23, 2005.
8. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M and Howell SB: Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62: 6559-6565, 2002.
9. Safaei R, Katano K, Samimi G, Naerdemann W, Stevenson JL, Rochdi M and Howell SB: Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother Pharmacol 53: 239-246, 2004.
10. Higashimoto M, Kanzaki A, Shimakawa T, Konno S, Naritaka Y, Nitta Y, Mori S, Shirata S, Yoshida A, Terada K, Sugiyama T, Ogawa K and Takebayashi Y: Expression of copper-transporting P-type adenosine triphosphatase in human esophageal carcinoma. Int J Mol Med 11: 337-341, 2003.
11. Kanzaki A, Toi M, Neamati N, Miyashita H, Oubu M, Nakayama K, Bando H, Ogawa K, Mutoh M, Mori S, Terada K, Sugiyama T, Fukumoto M and Takebayashi Y: Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma. Jpn J Cancer Res 93: 70-77, 2002.
12. Komatsu M, Sumizawa T, Mutoh M, Chen ZS, Terada K, Furukawa T, Yang XL, Gao H, Miura N, Sugiyama T and Akiyama S: Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 60: 1312-1316, 2000.
13. Ohbu M, Ogawa K, Konno S, Kanzaki A, Terada K, Sugiyama T and Takebayashi Y: Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human gastric carcinoma. Cancer Lett 189: 33-38, 2003.
14. Ferenci P: Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing. Hum Genet 120: 151-159, 2006.
15. Olivarez L, Caggana M, Pass KA, Ferguson P and Brewer GJ: Estimate of the frequency of Wilson's disease in the US Caucasian population: a mutation analysis approach. Ann Hum Genet 65: 459-463, 2001.
16. Koed K, Wiuf C, Christensen LL, Wikman FP, Zieger K, Moller K, von der Maase H and Orntoft TF: High-density single nucleotide polymorphism array defines novel stage and locationdependent allelic imbalances in human bladder tumors. Cancer Res 65: 34-45, 2005.
17. Sengelov L, Christensen M, von der Maase HD, Horn T, Marcussen N, Kamby C and Orntoft T: Loss of heterozygosity at 1p, 8p, 10p, 13q, and 17p in advanced urothelial cancer and lack of relation to chemotherapy response and outcome. Cancer Genet Cytogenet 123: 109-113, 2000.
18. Kiernan J: Histological and Histochemical Methods: Theory and Practice.: Pergamon Press New York, 1981.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
20. Aaboe M, Marcussen N, Jensen KM, Thykjaer T, Dyrskjot L and Orntoft TF: Gene expression profiling of noninvasive primary urothelial tumours using microarrays. Br J Cancer 93: 1182-1190, 2005.
21. Petrukhin K, Fischer SG, Pirastu M, Tanzi RE, Chernov I, Devoto M, Brzustowicz LM, Cayanis E, Vitale E, Russo JJ et al: Mapping, cloning and genetic characterization of the region containing the Wilson disease gene. Nat Genet 5: 338-343, 1993.
22. Thomas GR, Bull PC, Roberts EA, Walshe JM and Cox DW: Haplotype studies in Wilson disease. Am J Hum Genet 54: 71-78, 1994.
23. Thomas GR, Roberts EA, Walshe JM and Cox DW: Haplotypes and mutations in Wilson disease. Am J Hum Genet 56: 1315-1319, 1995.
24. Weirich G, Cabras AD, Serra S, Coni PP, Nurchi AM, Faa G and Hofler H: Rapid identification of Wilson's disease carriers by denaturing high-performance liquid chromatography. Prev Med 35: 278-284, 2002.
25. UniProt: UniProt Knowledgebase. 2010.
26. Wegman PP, Marcus NJ, Malakkaran BP and Wingren S: Biological significance of allele specific loss of the p53 gene in breast carcinomas. Breast Cancer Res Treat 118: 15-20, 2009.
27. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S and Sood AK: Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res 15: 3770-3780, 2009.
28. Martinez-Balibrea E, Martinez-Cardus A, Musulen E, Gines A, Manzano JL, Aranda E, Plasencia C, Neamati N and Abad A: Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy. Int J Cancer 124: 2905-2910, 2009.
29. Leonhardt K, Gebhardt R, Mossner J, Lutsenko S and Huster D: Functional interactions of CU-atpase ATP7B with cisplatin and the role of ATP7B in cells resistance to the drug. J Biol Chem 2009.
30. Uthus EO, Reeves PG and Saari JT: Copper deficiency decreases plasma homocysteine in rats. J Nutr 137: 1370-1374, 2007.